Luteolin offers novel therapeutic regimen in rotenone-induced Parkinson disease via modulation of TNF-α/FXMRP/serotonin/tyrosine hydroxylase signaling pathway. NJPS [Internet]. 11. April 2026 [zitiert 12. April 2026];40(2). Verfügbar unter: https://ojshostng.com/index.php/njphysiologicalsciences/article/view/4001